Уважаемые пользователи!
Мы рады представить вам новую версию сайта с улучшенным интерфейсом и новыми возможностями.
Приглашаем вас ознакомиться и поделиться обратной связью. Спасибо, что вы с нами!
Попробовать!

Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry

05.11.20141885
Due to a high burden of systemic cardiovascular events, current guidelines recommend the use of statins in all patients with peripheral artery disease (PAD).

Contractile Dysfunction of Left Ventricular Cardiomyocytes in Patients With Pulmonary Arterial Hypertension

31.10.20141729
What is the contribution of atrophy and contractility of cardiomyocytes to left ventricular (LV) dysfunction in patients with pulmonary arterial hypertension (PAH)?

CAS use increased, outcomes improved during recent 10-year period

30.10.20141828
Usage of carotid artery stenting increased and outcomes associated with that intervention improved between 2001 and 2010, recent findings concluded.

PROGNOSTIC VALUE OF ELEVATED LEVELS OF INTESTINAL MICROFLORA-GENERATED METABOLITE TRIMETHYLAMINE N-OXIDE IN PATIENTS WITH HEART FAILURE: THE GUT HYPOTHESIS REVISITED

29.10.20141832
Accumulation of intestinal microbial-dependent dietary phosphatidylcholine metabolite, trimethylamine N-oxide (TMAO), has been associated with coronary artery disease (CAD) pathogenesis.

Platelet Activation Is Associated With Myocardial Infarction in Patients With Pneumonia

28.10.20141649
What is the interplay between platelet overactivation and cardiovascular events during pneumonia?

Is There any Difference in Cardiogoniometry Parameters of Ischemic and Nonischemic Cardiomyopathy in Patients with Left Bundle Branch Block?

27.10.20141632
Differentiating ischemic from nonischemic cardiomyopathy is important both prognostically and therapeutically, although it may be difficult clinically.

Sotalol hydrochloride approved for treatment of ventricular arrhythmias, maintenance of normal sinus rhythm

25.10.20141703
Arbor Pharmaceuticals announced that the FDA has approved a new drug application for sotalol hydrochloride oral solution for the treatment of documented life-threatening ventricular arrhythmias and the maintenance of normal sinus rhythm in patients with a history of highly symptomatic atrial fibrillation or flutter.
Данный сайт и вся информация на нём предназначена для медицинских работников. Продолжая просмотр, вы соглашаетесь и подтверждаете, что являетесь медицинским работником.